Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $47.2852W HIGH $224.31
Volume
4.86 M
Value Traded
433.30 M
Short % Float
5.01%
-8.96%Week
-9.42%1 Month
+0.66%3 Month
+95.08%6 Month
+380.84%5 Year
+437.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
40.32 B
EPS (TTM)
-8.25
P/E Ratio
-
Ent. Value
36.87 B
Total Shares
214.34 M
Float Shares
193.04 M
Insiders
9.93%
Institutions
92.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RVMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Revolution Medicines, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revolution Medicines, Inc.
549Total events
20Upcoming
114Tier-1 (high impact)
2020 to 2044Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedRASONQUEApprovedTrial
Revolution Medicines begins treating patients in Phase 3 RASolute 309 trial of RASONQUE plus zoldonrasib in first-line metastatic RAS G12D PDAC
Metastatic RAS G12D Pancreatic Adenocarcinoma (PDAC)source ↗
▲Breakthrough Therapy DesignationRASONQUEApprovedDesignation
FDA grants Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus GnP for first-line metastatic PDAC
treatment-naïve metastatic pancreatic adenocarcinoma (PDAC)source ↗
▼Program DiscontinuationsabizabulinDiscontinuedCorporate
Discontinuation of sabizabulin development for chronic inflammation
chronic inflammation related to atherosclerotic cardiovascular diseasesource ↗
▲Patent GrantedenobosarmIP / Competition
Issued US patent for enobosarm with semaglutide
obesity with GLP-1 RAsource ↗
▲Partnership / LicenseenobosarmCorporate
Clinical supply agreement with Novo Nordisk for enobosarm
obesitysource ↗
▲PublicationRASONQUEApprovedPresentation
NEJM publishes Phase 1/2 data for RASONQUE in RAS mutant NSCLC
non-small cell lung cancersource ↗
▲Topline ReadoutDaraxonrasibApprovedClinical Data
RASolute 302 Phase 3 data reported: mOS 13.2 vs 6.6-6.7 months, HR 0.40
previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Topline ReadoutERAS-0015Clinical Data
Preliminary Phase 1 JYP0015M101 monotherapy data for ERAS-0015
KRAS G12X pancreatic ductal adenocarcinomasource ↗
▲PublicationDaraxonrasibApprovedPresentation
Phase 1/2 daraxonrasib data in RAS-mutant NSCLC published in NEJM
previously treated RAS-mutant NSCLCsource ↗
▲Preclinical PoCPRPPreclinical
PRP preclinical profile in advanced PDAC: >90% tumor-growth inhibition, >2.5-fold median OS extension
advanced pancreatic ductal adenocarcinoma (PDAC)source ↗
▲FDA ApprovalDaraxonrasibApprovedFDA Decision
FDA approves daraxonrasib for metastatic pancreatic cancer
metastatic pancreatic cancersource ↗
▲FDA ApprovalRASONQUEApprovedFDA Decision
FDA approved RASONQUE for metastatic pancreatic adenocarcinoma
metastatic pancreatic adenocarcinomasource ↗
▲Product LaunchRASONQUEApprovedPost-Market
RASONQUE available by prescription in the U.S.
metastatic pancreatic adenocarcinomasource ↗
●Oral PresentationRASONQUEApprovedPresentation
Webcast to discuss FDA approval
metastatic pancreatic adenocarcinomasource ↗
▲Partnership / LicenseCorporate
BeOne Medicines and Revolution Medicines announce clinical collaboration and regional rights agreement
RAS-addicted cancerssource ↗
▲FDA Filing AcceptedDaraxonrasibApprovedRegulatory Filing
FDA accepted NDA for daraxonrasib for previously treated metastatic PDAC
previously treated metastatic pancreatic cancersource ↗
●EU MAA SubmissionDaraxonrasibApprovedEx-US Regulatory
EMA initiated phased review of daraxonrasib under Cancer Medicines Pathfinder
pancreatic cancersource ↗
▲Breakthrough Therapy DesignationDaraxonrasibApprovedDesignation
FDA granted Breakthrough Therapy Designation to daraxonrasib for RAS mutant NSCLC
previously treated metastatic NSCLC with KRAS mutations other than G12Csource ↗
▲Orphan Drug DesignationDaraxonrasibApprovedDesignation
Swissmedic granted Orphan Drug Status to daraxonrasib
pancreatic cancersource ↗
▲Product LaunchDaraxonrasibApprovedPost-Market
U.S. commercial launch readiness achieved
previously treated metastatic PDACsource ↗
▲Trial InitiationZoldonrasibTrial
RASolve 308 recently initiated
first-line metastatic RAS G12D NSCLCsource ↗
▲Topline ReadoutZoldonrasibClinical Data
Initial data for zoldonrasib plus SOC in first-line NSCLC reported
first-line RAS G12D NSCLCsource ↗
▲Topline ReadoutElironrasibClinical Data
Initial data for elironrasib plus SOC in first-line NSCLC reported
first-line RAS G12C NSCLCsource ↗
▲Partnership / LicenseCorporate
Clinical collaborations with Summit Therapeutics, Tango Therapeutics, Bristol Myers Squibb
▲Other Regulator MilestoneDaraxonrasibApprovedEx-US Regulatory
Swissmedic granted Orphan Drug Status to daraxonrasib
pancreatic cancersource ↗
▲Primary Endpoint MetDaraxonrasibApprovedClinical Data
RASolute 302 met dual primary endpoints of OS and PFS
previously treated metastatic PDACsource ↗
▲QIDPDaraxonrasibApprovedDesignation
Selected for FDA Commissioner's National Priority Voucher pilot program
pancreatic cancersource ↗
▲Poster PresentationZoldonrasibPresentation
Phase 1/2 data for zoldonrasib presented at ESMO GI
metastatic PDACsource ↗
▲Preclinical PoCsabizabulinDiscontinuedPreclinical
Sabizabulin shows potent anticancer activity (IC50=18.2nM) in daraxonrasib-resistant pancreatic cancer cell lines
daraxonrasib-resistant KRAS-driven metastatic pancreatic cancersource ↗
▲FDA ApprovalDaraxonrasibApprovedFDA Decision
FDA approves daraxonrasib for pretreated metastatic pancreatic adenocarcinoma
pretreated metastatic pancreatic adenocarcinomasource ↗
▲FDA ApprovalRASONQUEApprovedFDA Decision
RASONQUE (daraxonrasib) approved by U.S. FDA for metastatic PDAC in patients who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy
Metastatic pancreatic adenocarcinoma (PDAC)source ↗
▲FDA Filing AcceptedDaraxonrasibApprovedRegulatory Filing
FDA accepted NDA for daraxonrasib for previously treated metastatic PDAC
previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
●NDA SubmissionDaraxonrasibApprovedRegulatory Filing
NDA submitted for daraxonrasib
previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
●EU MAA SubmissionDaraxonrasibApprovedEx-US Regulatory
EMA CHMP began phased review of daraxonrasib
previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
▲CHMP Positive OpinionDaraxonrasibApprovedEx-US Regulatory
EMA CHMP started phased review of daraxonrasib for pancreatic cancer
pancreatic cancersource ↗
●NDA SubmissionDaraxonrasibApprovedRegulatory Filing
Rolling NDA submission to FDA nearing completion
pancreatic cancersource ↗
◆Rolling Submission InitiatedDaraxonrasibApprovedRegulatory Filing
Rolling NDA submission to FDA nearing completion
pancreatic cancersource ↗
▲Oral PresentationZoldonrasibPresentation
Presentation of Phase 1 data for zoldonrasib plus daraxonrasib in second-line-plus RAS G12D metastatic PDAC at ESMO GI 2026
RAS G12D metastatic pancreatic ductal adenocarcinomasource ↗
▲Additional DataERAS-0015Clinical Data
July 2026 update: 57% uORR at 8 weeks at 32 mg recommended expansion dose
2L+ KRAS G12X pancreatic ductal adenocarcinomasource ↗
▲Topline ReadoutERAS-0015Clinical Data
July 2026 update: 57% uORR at 8 weeks at 32 mg RDE in 2L+ KRAS G12X PDAC
KRAS G12X PDACsource ↗
▲First Patient DosedZoldonrasibTrial
First patient dosed in RASolute 305 Phase 3 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D PDAC
metastatic RAS G12D pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationDaraxonrasibApprovedPresentation
RASolute 302 results presented at ASCO 2026 Plenary Session
previously treated metastatic PDACsource ↗
▲PublicationDaraxonrasibApprovedPresentation
RASolute 302 results published in NEJM
previously treated metastatic pancreatic cancersource ↗
▲Oral PresentationZoldonrasibPresentation
Phase 1/2 data for zoldonrasib presented at ESMO GI
metastatic PDACsource ↗
▲Oral PresentationDaraxonrasibApprovedPresentation
ASCO Plenary Session late-breaking presentation of RASolute 302 results
previously treated metastatic pancreatic ductal adenocarcinomasource ↗
▲Topline ReadoutDaraxonrasibApprovedClinical Data
Positive topline results from RASolute 302 trial
metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
▲PublicationDaraxonrasibApprovedPresentation
Results published in The New England Journal of Medicine
previously treated metastatic pancreatic ductal adenocarcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How RVMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-26 | Rasonque (daraxonrasib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B62 / 100
Pipeline Score
$7.6B
Pipeline Value
Not rated
Valuation Signal
6
Drugs Scored
-
rNPV / MCap
Top 5%
Mid Cap(rank 34 of 658)
Percentile Rank
Revolution Medicines, Inc. holds a solid B-grade pipeline (62/100), with $8.9B risk-adjusted pipeline value, led by Daraxonrasib in NSCLC (Non-small Cell Lung Cancer) (Phase 3), across $127B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Daraxonrasib Small moleculeMarketedNCT06625320 | Pancreatic Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 2,340 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every RVMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RASONQUE Breakthrough | metastatic non-small cell lung cancer | Phase 1/2 | 2026-09-02 | objective response rate: 42%; disease control rate: 89%; median progression free survival: 8.3 months; median overall survival: 16.0 months; grade 3 treatment related adverse events: 25%; most common adverse events: rash 8%, diarrhea 3%Read More | New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sandler Alan B.Officer (Chief Development Officer) | Option | 6,000 58,868 held | $58.84 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RVMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 10.7 % (101.9 %) | 2.14 B | 11.44 M | 19.76% ( 1.89 M) |
RVMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RVMD ranks across every disease it competes in
Competitive Position is a premium feature
See how RVMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRVMD News
RVMD▼ -6.1%today
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines has commenced patient treatment in the Phase 3 RASolute 309 trial, evaluating the combination of RASONQUE and zoldonrasib for metastatic RAS G12D pancreatic cancer. This trial aims to assess the efficacy of this dual therapy compared to standard treatments. The combination has shown promising results in earlier studies, addressing a significant unmet medical need.
Read more →RVMDAIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
AIM ImmunoTech's CEO highlighted Ampligen's potential in pancreatic cancer treatment following the FDA's approval of daraxonrasib. Ampligen demonstrated a median overall survival of 34.8 months in specific patient populations, significantly higher than historical controls. The company believes Ampligen can complement existing therapies and enhance patient outcomes in pancreatic cancer care.
Read more →RVMDPropanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Propanc Biopharma has positioned its lead candidate PRP as a complementary treatment to emerging RAS inhibitors from Revolution Medicines and Erasca. PRP promotes differentiation of malignant cells and reverses epithelial-mesenchymal transition (EMT), addressing residual cancer cell populations that persist after RAS pathway blockade. The company plans to initiate a Phase 1b study of PRP in early 2027.
Read more →RVMDRevolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Revolution Medicines announced that the FDA has granted Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in combination with chemotherapy for treatment-naïve metastatic pancreatic adenocarcinoma. This designation is based on encouraging preliminary data from clinical trials demonstrating antitumor activity. RASONQUE is already approved for patients who have received prior systemic therapy. The ongoing Phase 3 trial will further evaluate its efficacy.
Read more →RVMDVeru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Veru Inc. announced positive preclinical data for sabizabulin, demonstrating its ability to overcome resistance to daraxonrasib in pancreatic cancer. The drug showed potent anticancer activity in resistant cell lines and will advance into a planned Phase 2 clinical trial. This decision is supported by previous studies indicating sabizabulin's efficacy and safety. The company holds IP rights for sabizabulin until 2043.
Read more →RVMDNew England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines announced the publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in the New England Journal of Medicine. The study demonstrated promising efficacy in patients with RAS mutant non-small cell lung cancer (NSCLC), supporting the ongoing Phase 3 RASolve 301 trial. RASONQUE has also been approved by the FDA for metastatic pancreatic cancer, highlighting its potential across various RAS-driven cancers.
Read more →RVMDU.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The U.S. FDA has approved RASONQUE (daraxonrasib) for treating adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent therapy. In the Phase 3 RASolute 302 trial, RASONQUE demonstrated a 60% reduction in mortality risk and significant improvements in overall survival and quality of life compared to traditional chemotherapy. This marks a significant advancement in the treatment of pancreatic cancer.
Read more →RVMDRevolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
Revolution Medicines and BeOne Medicines have entered into a clinical collaboration to develop novel combinations of BeOne's oncology assets with Revolution's RAS(ON) inhibitors. This partnership focuses on RAS-addicted cancers and includes a regional rights agreement granting BeOne exclusive development and commercialization rights to four of Revolution's clinical-stage assets.
Read more →RVMDRevolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines reported strong progress in its clinical pipeline, particularly with daraxonrasib, which has received FDA acceptance for NDA review for metastatic pancreatic cancer. The company has also initiated an Expanded Access Program and achieved commercial launch readiness. Additionally, daraxonrasib received Breakthrough Therapy Designation for RAS mutant NSCLC. However, the company reported a significant net loss for the quarter.
Read more →RVMD▲ +6.2%on this news
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Revolution Medicines, Inc. will report its financial results for Q2 2026 on August 5, 2026, after market close. A webcast will follow at 4:30 p.m. ET to discuss the results and provide updates on corporate progress. The company specializes in developing targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced that the FDA has accepted its New Drug Application for daraxonrasib, a targeted therapy for previously treated metastatic pancreatic cancer. This decision follows promising results from the Phase 3 RASolute 302 trial, which demonstrated significant improvements in overall and progression-free survival. The company aims to expedite the drug's availability to patients.
Read more →RVMDEuropean Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Revolution Medicines announced that the European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, an investigational drug for pancreatic cancer, based on promising results from the Phase 3 RASolute 302 trial. The company is also nearing completion of a rolling NDA submission to the U.S. FDA. Daraxonrasib has been designated as an orphan medicinal product and is recognized for its potential to meet significant medical needs in pancreatic cancer treatment.
Read more →RVMDRevolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines presented promising Phase 1/2 clinical data for zoldonrasib in combination regimens targeting RAS G12D metastatic pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026. The trials demonstrated compelling antitumor activity and a manageable safety profile. The findings support ongoing and planned Phase 3 trials evaluating zoldonrasib in various treatment settings.
Read more →RVMDRevolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines announced that it will present clinical data from its RAS(ON) inhibitor combination trials at the 2026 ESMO Gastrointestinal Cancers Congress. The presentations will include results from Phase 1/2 trials of zoldonrasib in combination with chemotherapy and daraxonrasib. Additionally, two Phase 3 trials-in-progress will be showcased, focusing on daraxonrasib as a treatment for metastatic pancreatic ductal adenocarcinoma.
Read more →RVMDRevolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has commenced patient treatment in the RASolute 305 trial, which evaluates zoldonrasib combined with chemotherapy for metastatic RAS G12D pancreatic cancer. This Phase 3 trial aims to determine if the combination can enhance overall survival and progression-free survival. The study follows previous positive results from daraxonrasib, indicating the potential of RAS(ON) inhibitors in treating pancreatic cancer.
Read more →RVMDRevolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines announced that Steve Kelsey, M.D., will transition to a senior advisor role ahead of his planned retirement in January 2027. The company is restructuring its R&D leadership to maintain momentum in its oncology programs. Kelsey has been pivotal in advancing the company's drug development efforts since 2017.
Read more →RVMDPlatform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Biotechnology companies are increasingly focusing on enhancing existing therapies through advanced drug delivery technologies, particularly in oncology. Oncotelic Therapeutics is at the forefront with its Sapu003 program and Deciparticle platform, aiming to improve drug exposure and effectiveness. The global oncology drug market is expected to grow significantly, driven by rising cancer rates and advancements in treatment methods. However, challenges such as regulatory hurdles and high development costs remain prevalent.
Read more →RVMDRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced positive results from the Phase 3 RASolute 302 trial of daraxonrasib for previously treated metastatic pancreatic cancer. The trial showed unprecedented improvements in overall and progression-free survival compared to standard chemotherapy. Daraxonrasib also exhibited a manageable safety profile and improved quality of life for patients. The results will be presented at the ASCO Annual Meeting.
Read more →RVMDRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
Revolution Medicines announced a webcast on May 31, 2026, to discuss positive results from the Phase 3 RASolute 302 trial of daraxonrasib for metastatic pancreatic ductal adenocarcinoma. This follows the presentation of the trial data at the 2026 ASCO Annual Meeting. The company is focused on developing targeted therapies for RAS-addicted cancers.
Read more →RVMDRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines reported strong financial results for Q1 2026, highlighting the success of daraxonrasib in the Phase 3 RASolute 302 trial for metastatic pancreatic cancer. The company plans to submit these results to global regulatory authorities, including the FDA. Additionally, they raised $2.2 billion to support their RAS(ON) portfolio and continue advancing their clinical trials across various cancer types.
Read more →About Revolution Medicines, Inc.
Headquarters700 SAGINAW DR, REDWOOD CITY, CA, 94063
BIOPHARMAWATCH ELITE PLUS
Trade the next RVMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime